Article Text

Download PDFPDF
Successful treatment of psoriatic arthritis with rituximab
  1. J D Cohen
  1. Unité d’Immuno-Rhumatologie Clinique, Hôpital Lapeyronie, Montpellier, France
  1. Jean David Cohen, Unité d’Immuno-Rhumatologie Clinique, Hôpital Lapeyronie, 191 av du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France; jd-cohen{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Rituximab is a chimeric human/mouse monoclonal anti-CD20 antibody approved for the treatment of rheumatoid arthritis (RA) refractory to anti-tumour necrosis factor (TNF) therapy.1 Rituximab seems to be efficient in other diseases such as autoimmune cytopoenia,2 systemic lupus erythaematosus (SLE),3 dermatomyositis4 and Sjögren syndrome.5 To our knowledge, no case of psoriatic arthritis (PsA) treated by rituximab has been reported. Nevertheless, a partial remission of psoriasis following rituximab therapy for non-Hodgkin’s lymphoma has been reported.6 We describe the case of a man with severe PsA with dramatic improvement after rituximab treatment.

A 62-year-old Caucasian male had PsA since 2001 with asymmetrical arthritis involving distal interphalangeal arthritis, wrist, knee and ankle joint, and dactylitis. He has a personal (15 years ago) and …

View Full Text


  • Competing interests: None declared.

  • Patient consent: Obtained.